Loomba R et al., SYNERGY-NASH, NEJM 2024 (NEJMoa2401943, PMID 38856224) : tirzepatide and MASH, resolution in 62% at the 15 mg level
The Application of Ferroptosis in Diseases
Studies suggest that AOD9604 does not bind the growth hormone receptor and does not activate the JAK2/STAT5 pathway, which accounts for the absence of growth-promoting or IGF-1-elevating effects observed in animal studies
GSH is exclusively degraded at the extracellular level by cells expressing -glutamyltranspeptidase (GGT), such as those of the hepatobiliary tree and of other organs like the heart, kidney, lungs, pancreas, and seminal vesicles
The Bottom Line The FDA 503A Bulks List is a regulatory pathway for traditional compounding from certain active pharmaceutical ingredients
PMC 1769668